Daniel is a patent litigator in the UK. He acts for clients such as Merck, Lilly, Amgen and BMS. Recent key cases include Schutz v Werit (Supreme Court), Actavis v Lilly (Court of Appeal and currently pending before the Supreme Court), and BMS v Teva (availability of interim injunctions).
He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.
Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars and IAM Patent 1000.
A 'very sharp' up-and-coming partner who is 'developing a very good practice.'
'Daniel Brook is fast emerging as a leading patent litigator in cases concerning energy, electronics and life sciences. '
Areas of Focus
Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.
Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed and gemcitabine.
Acting for BMS in relation to patent challenges around its HIV products, efavirenz and atazanavir.
Acting for a number of electronic clients including ZTE, Qualcomm and BlackBerry on European patent litigation matters.
Chambers UK, Intellectual Property: Patent Litigation, 2014 onwards
Legal 500, Intellectual Property, 2013 onwards
UK, Rising Star 2013 and Super Lawyer 2015
IAM Patent 1000
Legal 500, Pharmaceuticals and biotechnology
Latest thinking and events
6 July, 2016
Sponsorships and Speaking Engagements
22 April 2015